Jason T Olin

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
    Jason T Olin
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Int J Geriatr Psychiatry 25:419-26. 2010
  2. ncbi Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living
    Jason T Olin
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Dement Geriatr Cogn Disord 29:510-5. 2010

Collaborators

Detail Information

Publications2

  1. ncbi Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
    Jason T Olin
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Int J Geriatr Psychiatry 25:419-26. 2010
    ..This was a 26-week, prospective, multicenter, single-arm, open-label pilot study to assess the safety and tolerability of rivastigmine capsules plus memantine in patients with moderate AD...
  2. ncbi Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living
    Jason T Olin
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Dement Geriatr Cogn Disord 29:510-5. 2010
    ..To investigate the effects of rivastigmine capsule 3-12 mg/day over 24 weeks on activities of daily living (ADLs) in patients with dementia associated with Parkinson's disease (PDD)...